MedWatch

Astrazeneca on vaccine skepticism: "Many forget it's a non-profit project"

The fact that many countries around the world are pausing the vaccine from Astrazeneca has no financial consequences for the pharmaceutical giant, according to the country director of Denmark and Norway. However, he does not rule out that the vaccine might suddenly be turned into a lucrative business.

Astrazeneca Country Director ( Managing Director) Denmark and Norway Christof Bischoff | Photo: Astrazeneca/PR/Ulrike Schacht

The Covid-19 vaccine from Astrazeneca has taken some hits since last week, when the European Medicines Agency (EMA) confirmed that the EMA's safety experts sees a possible connection between this vaccine and a series of rare but highly serious, and sometimes fatal, side effects.

Even though many countries have limited their use of the vaccine, and some – like Denmark – have opted to suspend it immediately, it does not seem like this will have any financial consequences for Astrazeneca. This firm runs all of its global vaccine sales as a non-profit project, and the company is regretful about the fact that people seem to forget this, as criticism is raining down on Astrazeneca in relation to the possible side effects of the vaccine on the one hand, and overdue deliveries on the other.

Read the whole article

Get 14 days free access.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Orphazyme cuts guidance following FDA setback

Friday's disappointing rejection letter from the US FDA is affecting Orphazyme's guidance for 2021. Now, the biotech firm forecasts an operating deficit of DKK 670-700m, up from DKK 100-150m.

Further reading

Related articles

Latest news

See all jobs